However, investors should keep a watch on sales figure for these devices to get a clear picture of the competition landscape. With rising adoption of DexCom devices by GLP-1 users, the potential impact of GLP-1 competition is likely to diminish. The presented facts imply that adoption of CGM devices is likely to continue going forward. Moreover, the use of these devices help increase the durability of health outcomes. The simplicity of CGM systems is supporting its accelerated adoption, even for patients on GLP-1 therapy. The company believes that the use of CGMs help patients to achieve dose titration for therapeutic regimen, as recommended in GLP-1 labeling. The use of CGMs also increased in patients on non-insulin therapy by 4.2 times. Per the data provided, use of these monitoring devices doubled on average for patients on intensive insulin while the same was up 3.8 times for patients on basal insulin alone. These devices are often paired with insulin pumps.ĭexCom presented that the use of CGMs have increased across all segments of patients with type II diabetes after beginning treatment with GLP-1 drugs. While GLP-1 are drugs that are prescribed with specific doses within regular intervals, CGM devices are worn on the body and can measure blood sugar in real time.
Image Source: Zacks Investment Research DexCom Findings The S&P 500 Index has gained 17.2% in the same time frame. Shares of DexCom have lost 5.3% year to date compared with the industry’s 4.8% decline. This caused DXCM’s shares to rise in the previous week. However, DexCom stated in its presentation last week that it has surveyed and observed rising adoption of its CGM devices among patients initiating GLP-1 therapy, contradicting the assumptions.
0 kommentar(er)
